Biopharmaceutical services company Quintiles has appointed Oren Cohen as senior vice president and global head of its Phase I clinical research division, which includes facilities in Overland Park, Kansas (US), London (UK) and Hyderabad (India).
Cohen will leverage Quintiles’ breadth of clinical trial services and expertise in biomarker development to provide clients with an integrated early clinical development platform that reduces overall study costs, simplifies trial management and accelerates development, while ensuring quality and patient safety.
Cohen joined Quintiles as a medical advisor in 2001 and was appointed chief medical and scientific officer (CMSO) in 2004. He is consulting Professor of Medicine at Duke University Medical Center and a Fellow of the Infectious Diseases Society of America.
‘The Phase I clinical research space is changing rapidly, with fewer new molecules entering development and a fundamental shift in target study populations from healthy volunteers to patient groups,’ said Cohen.
‘Biopharma companies are looking for an ally to help them manage these complexities, ensure patient safety and reduce costs, and Quintiles offers best-in-class early clinical development solutions to meet its customers’ needs.’
Quintiles appoints global head of Phase I division
CMSO Oren Cohen takes the role
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
Right-sized, not oversized: rethinking quality management technology for the UK's growing manufacturers (part II)
How the enterprise trap is set: familiar platforms, borrowed requirements and hidden validation costs can turn seemingly safe purchasing decisions into costly operational burdens
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
The cost of complexity: why mid-tier manufacturers need to rethink regulatory technology strategy (part II)
Mid-tier manufacturers can avoid over-engineering by questioning scale, users and integrations, then prioritising built-in GMP workflows, integrated platforms and industry expertise, freeing budget to invest in future capabilities
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
The cost of complexity: why mid-tier manufacturers need to rethink regulatory technology strategy (part I)
With the right questions and scrutiny during procurement, organisations can avoid the over-engineering trap and select a QMS solution that fits their requirements and allows them to remain competitive
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Quality management during manufacturing changes: part I
Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards